European Reference Network
ERN-RITA is an EU-funded virtual network coordinating 71 reference centres in 25 European countries to improve diagnosis and care of patients with rare immunodeficiency, autoinflammatory, autoimmune, and paediatric rheumatic diseases, via the CPMS consultation platform and the RITA Registry.
- Company typePrivate
- Founded2017
- HeadquartersUtrecht, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingServices
What European Reference Network does
ERN-RITA (European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases) is a publicly funded virtual healthcare network established in 2017 under the European Commission's European Reference Network programme, one of 24 ERNs launched that year. It coordinates multidisciplinary expertise across 71 reference centres in 25 European countries, engaging 300+ health professionals across four disease streams: Primary Immunodeficiencies (PID), Autoinflammatory Disorders (AID), Autoimmune Diseases (AI), and Paediatric Rheumatic Diseases (PR). The network is coordinated by UMC Utrecht (Netherlands) and works in partnership with six core scientific societies (ESID, EUVAS, ISSAID, PReS, PRINTO, EUROFEVER) and patient organisations via the RITA Patient Advisory Group (RIPAG).
The network operates a portfolio of digital infrastructure and programmes that together form its service offering. The Clinical Patient Management System (CPMS) is the core platform enabling virtual advisory-board consultations across borders without patient travel. The RITA Registry, built on Castor EDC (ISO 27001 certified) and operational from January 2024, collects Common Data Elements as defined by the European Commission, with first patients entered in August 2025. Additional offerings include patient journey educational tools, a junior clinician mobility programme, clinical guidelines development, model care pathways (developed under the JARDIN Joint Action), and a regular webinar series ("Tuesday Lunch with RITA"). Underlying integrations include Castor EDC for registry data, Zoom for webinar delivery, and Google Maps for centre location.
ERN-RITA does not operate a commercial business model. Services are provided free of charge to patients and healthcare providers, with operations funded entirely by the European Union through the EU4H grant programme covering 2023-2027. Access is facilitated by the Cross-Border Healthcare Directive (2011/24/EU). There is no pricing model, no commercial sales motion, and the coordinating team is 1-10 employees. Growth and expansion are driven by EU mandate, scientific society partnerships, and participation in Joint Actions (such as JARDIN) rather than by commercial revenue mechanics.
European Reference Network firmographics
Firmographics- Name
- European Reference Network
- Legal name
- European Reference Network RITA (ERN-RITA)
- Website
- https://ern-rita.org
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ERN-RITA is an EU-funded virtual network coordinating 71 reference centres in 25 European countries to improve diagnosis and care of patients with rare immunodeficiency, autoinflammatory, autoimmune, and paediatric rheumatic diseases, via the CPMS consultation platform and the RITA Registry.
- Ownership category
- akta.pro rank
European Reference Network industry classification
Industry- Product category
- Rare Disease Healthcare Network
- NAICS
- Health Care and Social Assistance (62), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- HIE Platforms & Network Services (Community/Regional/National) (HLACABAB)
- akta.pro secondary industry
- Patient Engagement, Education & Messaging Platforms (portal/CRM integrated) (HLALABAJ)
Keywords
Where European Reference Network is headquartered
LocationHeadquarters
- HQ city
- Utrecht
- HQ country
- Netherlands
- HQ region
- Europe
Offices3 records
Markets served
European Reference Network business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- EU Public Funding: ERN-RITA is funded under EU4H (EU4Health) grant programme covering 2023-2027. No commercial revenue is generated. The network coordinates expert healthcare across borders at no cost to patients, facilitated by Cross-Border Healthcare Directive (2011/24/EU).
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
European Reference Network product offering
Product offeringCore offering
European Reference Network (ERN-RITA) is a virtual European healthcare coordination network connecting 71 reference centres and over 300 health professionals across 25 countries for the diagnosis and treatment of rare immunological disorders. It operates a Clinical Patient Management System (CPMS) for virtual multidisciplinary consultations, the RITA Registry for patient data capture, and produces clinical guidelines, care pathways, and educational programmes spanning four disease streams: Primary Immunodeficiencies, Autoinflammatory Disorders, Autoimmune Diseases, and Paediatric Rheumatic diseases.
Product overview
ERN-RITA (European Reference Network for Rare Immunodeficiency, Autoinflammatory, Autoimmune Diseases and Paediatric Rheumatology) is a network connecting physicians, researchers, patients and patient representatives across Europe. The organization operates multiple interconnected digital platforms and programs: the RITA Registry (built on Castor EDC) for patient data collection; CPMS for virtual clinical consultations; Patient Journeys as educational tools; and supports Clinical Guidelines development, Care Pathways standardization, a Mobility Programme for junior professionals, RIPAG for patient engagement, and Educational Webinars. The network organizes its activities across four disease streams: Primary Immunodeficiencies (PID), Autoinflammatory Disorders (AID), Autoimmune Diseases (AI), and Paediatric Rheumatology (PR), spanning 71 reference centers across 25 countries.
Differentiator
Problem solved
Functional benefit
Products and services
- RITA Registry A patient registry built on Castor EDC that collects Common Data Elements for patients diagnosed with rare immunological diseases from January 2024 onwards, with ISO 27001 certified pseudonymization capabilities.
- CPMS (Clinical Patient Management System) An online platform enabling complex patient cases to be discussed by multidisciplinary medical experts across different disciplines and countries without requiring patient travel.
- Patient Journeys Visual educational tools describing patient experiences living with rare immunological diseases, covering conditions including CVID, Small Vessel Vasculitis, Familial Mediterranean Fever, Hereditary Angioedema, and Juvenile Idiopathic Arthritis.
- Mobility Programme A professional development initiative enabling junior medical professionals to visit leading healthcare providers within the ERN-RITA network for short-term exchanges of 3-5 working days to gain hands-on experience in immune disorder management.
- Care Pathways Standardized, patient-centred care pathways for rare diseases developed in collaboration with the JARDIN project, with current focus on a model care pathway for autoinflammatory diseases.
- Clinical Guidelines Development Initiative to develop and endorse clinical guidelines for rare immunological disorders, with processes for both developing new guidelines and endorsing existing ones from partner scientific societies.
- RIPAG (RITA Patient Advisory Group) Patient-centred engagement framework bringing patient representatives together across four disease streams to contribute to network activities, governance, and ensure patient-centric approach in all ERN-RITA initiatives.
- Educational Webinars Regular webinar series organized by ERN-RITA featuring expert presentations on rare immunological conditions such as ANCA-associated vasculitis, IgA vasculitis, primary CNS vasculitis, and cryoglobulinemic vasculitis.
Quantifiable outcome
- 71 reference centres in 25 countries serving patients across Europe
- +5 more outcomes
Companies that use European Reference Network
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
European Reference Network technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature3 records
European Reference Network partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- European Society for Immunodeficiencies (ESID)coreESID is a core scientific partner of ERN-RITA. The society contributes to guideline development, registry coordination (linked ESID registry), research collaboration, and professional education. ESID representation is present in RITA governance (Ex-officio member).
- European Vasculitis Society (EUVAS)coreEUVAS collaborates with ERN-RITA on autoimmune vasculitis topics, including clinical guidelines, webinars (e.g., joint Tuesday Lunch with RITA sessions during Vasculitis Awareness Month), and shared educational content.
- International Society of Autoinflammatory Diseases (ISSAID)coreISSAID works with ERN-RITA on autoinflammatory disease guidelines, including the ongoing USAID (Undifferentiated Systemic Autoinflammatory Diseases) consensus guidelines project. The ISSAID logo appears on ERN-RITA scientific society listings.
- Paediatric Rheumatology European Society (PReS)corePReS is a core scientific partner represented in RITA governance (Ex-officio member). Collaborates on paediatric rheumatology guidelines, the PReS Congress, and transition care programmes for adolescent patients.
- Paediatric Rheumatology International Trials Organisation (PRINTO)corePRINTO collaborates on clinical guidelines, the Eurofever registry (linked to RITA's registry activities), and international research projects for paediatric rheumatology conditions.
- EUROFEVERcoreEUROFEVER runs a registry for autoinflammatory diseases that is linked to the RITA Registry to ensure identification of all patients with immune-mediated conditions and avoid duplicate data entry.
- IPOPI (International Patient Organisation for Primary Immunodeficiencies)coreIPOPI is represented in RITA governance (Johan Prevot as Patient Organisations representative on the Board). Contributes to patient advocacy, CVID patient journeys, and PID awareness across Europe.
- EURORDIS (European Organisation for Rare Diseases)coreEURORDIS played a critical role in establishing all 24 ERNs and continues to ensure patient representation. ERN-RITA works with EURORDIS through ePAG (European Patient Advocacy Groups) for patient-centric governance.
- JARDIN (Joint Action on Integration of ERNs into National Health Systems)coreJARDIN is a EU-funded initiative supporting integration of ERNs into national healthcare systems. ERN-RITA participates in Work Package 6.2 developing model care pathways for autoinflammatory diseases, testing and refining the JARDIN toolkit.
- Castor EDCcoreCastor EDC provides the data capture platform for the RITA Registry. It is ISO 27001 certified and creates pseudonyms for every registered patient. This is an inbound technology partnership rather than a commercial vendor relationship.
- Vasculitis Ireland AwarenessminorPatient organisation represented in RIPAG governance and the RITA Board. Contributes to vasculitis-specific patient journeys and awareness activities.
- FMF & AID Global AssociationminorPatient organisation representing Familial Mediterranean Fever and autoinflammatory disease patients. Active in RIPAG and contributes to patient journey documentation and disease awareness.
- ENCA (European Network for Children with Arthritis)minorENCA represents the global network for children with arthritis and autoinflammatory conditions. Listed as a patient organisation partner in RITA governance.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
European Reference Network competitors and assessment
Company assessmentRegional players
- National Organization for Rare Disorders (NORD): US-based umbrella organisation for rare disease patient advocacy and research. Comparable in mission of rare disease coordination and patient representation but operates in a different regulatory and healthcare system.
- Rare Diseases Clinical Research Network (RDCRN): NIH-funded US network of clinical research consortia studying rare diseases. Functionally analogous in bringing together multiple disease-focused consortia, with similar registry, research, and care-coordination models but US-centric reach.
Direct peers
- Orphanet: European reference portal for rare diseases and orphan drugs, providing expert-cured knowledge, nomenclature (Orpha codes used by RITA), and a directory of expert centres. Functions as a complementary data and classification infrastructure for the rare disease ecosystem ERN-RITA serves.
- ERN-RARE-LIVER: European Reference Network for rare liver diseases. Functions as a structural peer with same network model, EU funding mechanism, and multi-country HCP membership structure across rare disease specialty areas.
- ERN-EuroBloodNet: European Reference Network for rare haematological diseases. Sister ERN operating under the same EU4H grant structure with parallel registry, virtual consultation, and cross-border referral capabilities.
- ERN-EpiCARE: Another European Reference Network focused on rare epilepsies. Operates under the same EU regulatory framework, EU4H funding model, and CPMS virtual consultation infrastructure, with comparable governance and patient organisation engagement.
- ESID Registry: European Society for Immunodeficiencies Registry - the legacy primary immunodeficiency registry linked to RITA Registry. Direct peer in disease coverage (PID) with longer operational history and more mature dataset, serving overlapping centres and clinicians.
- European Joint Programme on Rare Diseases (EJP RD): EU-funded programme coordinating rare disease research, training, and data resources across Europe. Highly comparable in funding model, transnational scope, and stakeholder engagement, with overlapping registry and research infrastructure.
Broad incumbents
- EURORDIS - Rare Diseases Europe: European Organisation for Rare Diseases serving as an umbrella patient advocacy body. Sits at the parent level of the ERN ecosystem and coordinates patient representation (ePAG) across all 24 ERNs including RITA, giving it broader scope but adjacent positioning.
Others
- Castor EDC: Clinical data capture platform provider powering the RITA Registry. Direct technology partner and enabler; comparable in data infrastructure capabilities but operates as a commercial vendor rather than a peer network.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
European Reference Network social profiles
Digital presenceEuropean Reference Network financial estimates
Financial estimateRevenue estimate
Valuation estimate
European Reference Network leadership team
Management profileNumber of profiles
Profiles16 records
European Reference Network funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
European Reference Network M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about European Reference Network
What does European Reference Network do?
European Reference Network (ERN-RITA) is a virtual European healthcare coordination network connecting 71 reference centres and over 300 health professionals across 25 countries for the diagnosis and treatment of rare immunological disorders. It operates a Clinical Patient Management System (CPMS) for virtual multidisciplinary consultations, the RITA Registry for patient data capture, and produces clinical guidelines, care pathways, and educational programmes spanning four disease streams: Primary Immunodeficiencies, Autoinflammatory Disorders, Autoimmune Diseases, and Paediatric Rheumatic diseases.
Is European Reference Network a public or private company?
European Reference Network is a private company. It is classified as state government owned and is currently operating.
When was European Reference Network founded?
European Reference Network was founded in 2017. It employs 1 to 10 people.
Where is European Reference Network based?
European Reference Network is headquartered in Utrecht, Netherlands, in the Europe region.
How does European Reference Network make money?
One revenue line is on record: EU Public Funding.
Who are European Reference Network's main competitors?
Regional players on record are National Organization for Rare Disorders (NORD) and Rare Diseases Clinical Research Network (RDCRN). Direct peers are Orphanet, ERN-RARE-LIVER, ERN-EuroBloodNet, ERN-EpiCARE, ESID Registry and European Joint Programme on Rare Diseases (EJP RD). EURORDIS - Rare Diseases Europe is listed as a broad incumbent. Castor EDC is listed as an others.
Does European Reference Network have an API?
No public API is recorded for European Reference Network.
What industry is European Reference Network in?
European Reference Network's product category is Rare Disease Healthcare Network. Its primary akta.pro industry code is HLACABAB, HIE Platforms & Network Services (Community/Regional/National), with a secondary code of HLALABAJ, Patient Engagement, Education & Messaging Platforms (portal/CRM integrated). Its NAICS code is 62 and its SIC code is 8000.